GMP Pharma-Grade Cannabis
Canndoc has been pioneering Pharma-Grade cannabis for more than 14 years. Over the years, Canndoc provided millions doses of to 40,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.
Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.
At Our Core
As governmental regulation spreads across the globe, more than 40 countries are adopting regulations that allow the use of cannabis for medical purposes. Our operations already encompass the entire value chain, from genetics, cultivation and production to sales and distribution, to meet the needs of pharma-grade cannabis for patients, doctors and pharmacies around the world.
14+ years of product development
We are bringing medical cannabis into the 21ˢᵗ century with pharma-grade treatments for patients. Our GMP standard products are prescribed for a range of indications including Neuropathic pain, Relief of pain of cancerous source, Inflammatory bowel disease, Post-traumatic stress disorder, Parkinson’s, Epileptic seizures and more.
Our products and genetics cover European, Canadian and Israeli regulatory requirements.
Research & Development
For more than 14 years our research has contributed to the advancement of medical cannabis through cutting-edge therapeutic development and building a portfolio of GMP products with efficacy as a top priority. We’re focused on validating our clinical significance through clinical trials with hospitals and universities.
Based on our proprietary database of more than 40,000 patients and millions of doses, we initiated an array of clinical trials to validate the beneficial effect of our GMP pharma-grade cannabis on various indications: adult epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy, parkinson, rheumatoid arthritis, radicular pain, PTSD, and lumbar radiculopathy.
Company News & Updates
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for
CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth
The former Israeli prime minister has warrants worth NIS 18 million in the Israeli medical cannabis company
Subversive Acquisition LP Announces InterCure’s Agreement With Cookies to Expand the Iconic Cannabis Brand Across Europe
Subversive Acquisition LP Announces InterCure’s Letter of Intent Relating to the Acquisition of a Multi-National Medical Cannabis Producer, Better Holdings
Uruguayan Cannabis Co. Fotmer Life Sciences Signs Supply Agreement With Israel-Based Canndoc
Mr. Barak has served as Canndoc’s board of Directors Chairman since March 2019. Prior his election as Prime Minister in 1999, Mr. Barak completed an illustrious 36 years career in the IDF as the most decorated soldier in its history. Mr. Barak has a B.Sc. in physics and Mathematics from the Hebrew University, Jerusalem and a M.Sc. degree in Economic-Engineering Systems from Stanford University, California. Mr. Barak currently serves on the board of Intercure Ltd. and two other Israeli companies: Carbyne Ltd., and Cybertoka Ltd.
We welcome questions regarding our company and product portfolio. You can reach us by filling out the contact form below or through email. For general medical information or medical condition-specific inquiries, please contact your healthcare provider.
Your submission has been received!